SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 99,000 shares, an increase of 148.1% from the November 15th total of 39,900 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average trading volume of 90,700 shares, the days-to-cover ratio is currently 1.1 days.

SAB Biotherapeutics Trading Up 5.4 %

Shares of NASDAQ:SABS traded up $0.21 on Friday, reaching $4.08. 31,140 shares of the company traded hands, compared to its average volume of 35,255. SAB Biotherapeutics has a 52 week low of $2.16 and a 52 week high of $8.40. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The business’s 50-day simple moving average is $3.14 and its 200 day simple moving average is $2.92.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics as of its most recent SEC filing. 7.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price for the company. Chardan Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Finally, Oppenheimer reissued an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SAB Biotherapeutics has an average rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.